

ABSTRACT OF THE DISCLOSURE

Novel glycosylated intracellular IL-1 receptor antagonist type II (icIL-1ra-II) is expressed and secreted in mammalian cells transformed with an expression vector where icIL-1ra-II is secreted by expressing icIL-1ra-II fused to the human growth hormone signal peptide. Also disclosed are a pharmaceutical composition containing glycosylated icIL-1ra-II as an active ingredient and a method for reducing IL-1 levels in patients having a condition involving overexpressed IL-1.

D 10 f:\user\22\roger\amitail.app